| Audience | Patients, caregivers, clinicians, and cannabis-science readers interested in perioperative glucose management in cardiac surgery |
| Primary Topic | perioperative liraglutide in adults undergoing cardiac surgery |
| Source | Read the full source |
Liraglutide Around Cardiac Surgery: What Four Randomized Trials Did Not Establish
A meta-analysis of four randomized cardiac-surgery trials found no clear liraglutide effect on 30-day mortality, overall postoperative complications, cardiac adverse events, hypoglycemia, or nausea and vomiting. Wide confidence intervals and only 446 randomized patients limit certainty.
| Study Type | Systematic review and meta-analysis of randomized controlled trials |
| Evidence Base | Seven reports from four trials, with 446 randomized adults undergoing cardiac surgery |
| Intervention | Perioperative subcutaneous liraglutide |
| Comparators | Placebo or insulin-based usual care |
| Mortality | 30-day mortality: 1 of 161 versus 3 of 160; RR 0.42, 95% CI 0.06 to 2.81 |
| Any Postoperative Complication | RR 0.92, 95% CI 0.74 to 1.14 |
| Cardiac Adverse Events | RR 1.08, 95% CI 0.83 to 1.40 |
| Hypoglycemia | 8 of 165 versus 9 of 166; RR 0.85, 95% CI 0.34 to 2.13 |
| Nausea and Vomiting | RR 3.01, 95% CI 0.26 to 35.27 |
| Published | September 4, 2026 |
| PMID / DOI | 42693519 / 10.1097/CRD.0000000000001465 |
| Sourcing Boundary | Full text was unavailable; the PubMed abstract did not report the glycemic efficacy estimates named in the article title |
The review included 446 randomized patients across four trials reported in seven publications.
Randomized evidence is valuable, but this total is limited for mortality, uncommon complications, and subgroup questions.
There was one death among 161 liraglutide participants and three among 160 controls within 30 days.
The risk ratio confidence interval ranged from substantial benefit to substantial harm, so the estimate does not establish a mortality effect.
The pooled risk ratio for any postoperative complication was 0.92, with a 95% confidence interval from 0.74 to 1.14.
That interval includes no difference and does not justify a claim that liraglutide prevents postoperative complications.
Cardiac adverse events and hypoglycemia were not statistically different between groups in the reported analyses.
The nausea and vomiting estimate was exceptionally imprecise, with a confidence interval from 0.26 to 35.27, leaving clinically important uncertainty.
Although glycemic efficacy appears in the article title, the available PubMed abstract does not provide pooled glucose or insulin-use estimates.
Without accessible full text, those outcomes cannot be responsibly reconstructed or summarized from the title alone.
Perioperative GLP-1 decisions require separate consideration of chronic indications, fasting and aspiration concerns, glucose control, insulin protocols, gastrointestinal symptoms, and surgical context.
A meta-analysis can organize small randomized trials, but pooling cannot replace missing event numbers, complete outcome reporting, or adequately powered contemporary trials.
This synthesis is most useful as a map of uncertainty. The reported clinical and safety outcomes were not clearly different, while several estimates were too imprecise to exclude meaningful benefit or harm.
I would not use the abstract alone to start, stop, hold, or continue liraglutide around surgery. Those decisions belong with the surgical, anesthesia, diabetes, and prescribing teams using current patient-specific guidance.
How to Interpret This Perioperative Liraglutide In Adults Undergoing Cardiac Surgery Evidence Without Overstating It
A useful evidence report should let the signal breathe without inflating it.
The right question is not whether the paper is positive or negative, but what kind of decision it can responsibly support.
A Four-Step Reading Frame
Evidence type
Start by identifying whether the paper is a randomized trial, review, meta-analysis, observational study, or protocol.
Population
Ask whether the studied population matches the patient or clinical scenario involving perioperative glucose management in cardiac surgery.
Outcome meaning
Look at what actually changed, how it was measured, and whether the change would matter in daily life.
Safety and uncertainty
Read limitations and adverse effects as part of the result, not as a footnote.
Eight Clinical Ways to Read This Evidence
Distinct implications for patients, clinicians, methods, safety, and future research
A Meta-analysis Is Not a Perioperative Instruction
The review combined four randomized trials of liraglutide around cardiac surgery. Its reported abstract outcomes did not show clear differences in mortality, overall complications, cardiac adverse events, hypoglycemia, or nausea and vomiting.
That does not tell an individual patient whether to hold or continue medication before surgery. Aspiration risk, gastrointestinal symptoms, diabetes control, fasting instructions, drug indication, procedure type, and anesthesia planning require a coordinated decision from the treating teams.
The Reported Endpoints Are Mostly Inconclusive
The pooled risk ratios for overall complications, cardiac adverse events, and hypoglycemia included the null. Mortality events were rare, and the confidence interval was too wide to establish benefit or harm across ordinary cardiac-surgery settings.
Clinicians should avoid converting non-significance into equivalence or safety proof. The evidence supports uncertainty about these outcomes in a small randomized literature. Perioperative decisions still need contemporary guidance, glucose-management plans, and patient-specific assessment rather than a pooled estimate alone.
Four Deaths Cannot Settle Survival
The abstract reports one death among 161 liraglutide participants and three among 160 controls within 30 days. The pooled risk ratio was 0.42, but its 95 percent confidence interval ran from 0.06 to 2.81.
That interval includes a large possible reduction, no effect, and a substantial possible increase. The numerical imbalance is not proof of protection. Much larger trials or high-quality pooled data are needed before survival can influence routine perioperative liraglutide decisions.
A Broad Composite Can Hide Different Outcomes
Any postoperative complication occurred in 68 of 129 liraglutide participants and 76 of 132 controls, producing a risk ratio of 0.92 with a 95 percent confidence interval from 0.74 to 1.14 in the pooled analysis.
The result does not establish prevention of complications. A broad composite can also combine events with different severity and mechanisms. Without accessible full text, this report cannot responsibly reconstruct every component, timing definition, or individual trial-level contribution.
Hypoglycemia Was Not Clearly Reduced
Hypoglycemia occurred in 8 of 165 liraglutide participants and 9 of 166 controls. The risk ratio of 0.85 had a 95 percent confidence interval from 0.34 to 2.13, leaving the direction unresolved.
The estimate is compatible with benefit, no effect, or harm. Although glucose-dependent pharmacology provides a rationale for study, mechanism does not substitute for outcome precision. Glucose monitoring and rescue protocols remain necessary in cardiac surgery for every treatment group.
The Nausea Estimate Is Exceptionally Uncertain
For postoperative nausea and vomiting, the pooled risk ratio was 3.01, but the 95 percent confidence interval ranged from 0.26 to 35.27. Such a wide interval signals sparse data and a notably unstable estimate.
This result neither proves an increase nor provides reassurance. Gastrointestinal symptoms matter in perioperative care because they may affect fasting, aspiration assessment, hydration, and recovery. Patient-specific symptom review remains more actionable than this imprecise pooled number.
The Abstract Omits Glycemic Efficacy Results
The article title names glycemic efficacy, but the complete PubMed abstract does not report pooled glucose levels, insulin requirements, time in range, or other glycemic estimates. Full text was not available through PMC or an open-access location.
Those missing results cannot be inferred from the title, pharmacology, or prior trials. This report therefore limits itself to the outcomes explicitly available and identifies the omission. Complete appraisal should await access to the full article.
Perioperative Trials Need More Than Surrogate Control
Future trials should be large enough for clinically important complications and should report glucose control, insulin exposure, hypoglycemia, aspiration-related events, gastrointestinal symptoms, length of stay, and patient-centered recovery outcomes with consistent definitions across participating surgical centers.
They should also distinguish chronic users from newly initiated perioperative treatment and account for procedure type, diabetes status, dose, fasting plan, and comparator insulin protocol. Better harmonization and complete reporting would make future pooling more informative.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
Frequently Asked Questions
What did the liraglutide review examine?
It pooled randomized trials of perioperative subcutaneous liraglutide versus placebo or insulin-based usual care in adults undergoing cardiac surgery.
How much evidence was included?
Seven reports from four randomized trials included 446 randomized patients.
Did liraglutide reduce 30-day mortality?
No clear effect was established. Only four deaths were reported, and the confidence interval was very wide.
Did liraglutide reduce postoperative complications?
No statistically clear difference was found for the composite of any postoperative complication.
Did liraglutide reduce cardiac adverse events?
No statistically clear difference was reported for cardiac adverse events.
Did liraglutide reduce hypoglycemia?
No clear reduction was established; the confidence interval included meaningful benefit and harm.
What did the review find about nausea and vomiting?
The estimate was highly imprecise, ranging from possible reduction to a very large increase.
Were glycemic efficacy results available?
The accessible PubMed abstract did not report the glycemic estimates named in the title, and full text was unavailable.
Should patients stop liraglutide before surgery?
This meta-analysis does not make that decision. Patients need individualized instructions from their prescribing, surgical, anesthesia, and diabetes teams.
What is the main evidence limitation?
Only four small trials were available, event counts were low, and several pooled estimates were too imprecise for firm conclusions.
